Abstract
In spite of almost 60 years of experience with the pharmacological treatment of schizophrenia, there is still a large unmet medical need for better control of especially the negative and cognitive symptoms of schizophrenia. One potential new avenue is the selective blockade of histamine H3 receptors (H3R). Based on a large basis of preclinical data, H3R antagonists or inverse agonists have been suggested to improve cognition in a variety of neurological and psychiatric indications. The aim of the present paper is to review the potential usefulness of H3R antagonists for the treatment of schizophrenia. Although, so far no H3R antagonist has been marketed and many phase II and III studies are still underway, the available data seem to indicate that H3R antagonists may not be primarily effective against the positive symptoms (i.e. the psychotic symptoms such as hallucinations and delusions) but may hold a promise as add-on therapy for selectively improving cognitive and perhaps negative symptoms.
Keywords: Schziphrenia, positive symptoms, cognitive symptoms, animal models, H3 receptors, drug discovery.
Current Pharmaceutical Design
Title:Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?
Volume: 21 Issue: 26
Author(s): Bart A. Ellenbroek and Bibinaz Ghiabi
Affiliation:
Keywords: Schziphrenia, positive symptoms, cognitive symptoms, animal models, H3 receptors, drug discovery.
Abstract: In spite of almost 60 years of experience with the pharmacological treatment of schizophrenia, there is still a large unmet medical need for better control of especially the negative and cognitive symptoms of schizophrenia. One potential new avenue is the selective blockade of histamine H3 receptors (H3R). Based on a large basis of preclinical data, H3R antagonists or inverse agonists have been suggested to improve cognition in a variety of neurological and psychiatric indications. The aim of the present paper is to review the potential usefulness of H3R antagonists for the treatment of schizophrenia. Although, so far no H3R antagonist has been marketed and many phase II and III studies are still underway, the available data seem to indicate that H3R antagonists may not be primarily effective against the positive symptoms (i.e. the psychotic symptoms such as hallucinations and delusions) but may hold a promise as add-on therapy for selectively improving cognitive and perhaps negative symptoms.
Export Options
About this article
Cite this article as:
Ellenbroek A. Bart and Ghiabi Bibinaz, Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?, Current Pharmaceutical Design 2015; 21 (26) . https://dx.doi.org/10.2174/1381612821666150605105325
DOI https://dx.doi.org/10.2174/1381612821666150605105325 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Green Aqueous Synthesis of Mono, Bis and Trisdihydropyridines Using Nano Fe<sub>3</sub>O<sub>4</sub> Under Ultrasound Irradiation
Current Organic Synthesis Trends in Metabolic Syndrome and Gene Networks in Human and Rodent Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting TRP Channels in Airway Disorders
Current Topics in Medicinal Chemistry Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Pulmonary Arterial Hypertension in Connective Tissue Diseases
Current Respiratory Medicine Reviews Statin Attenuates High Glucose-Induced and Angiotensin II-Induced MAP Kinase Activity Through Inhibition of NAD(P)H Oxidase Activity in Cultured Mesangial Cells
Medicinal Chemistry Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets Electrocardiogram in Andersen-Tawil Syndrome. New Electrocardiographic Criteria for Diagnosis of Type-1 Andersen-Tawil Syndrome
Current Cardiology Reviews Cancer and Treatment Modalities
Current Cancer Therapy Reviews Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design Prevalence of Obesity, Hypertension, Diabetes, and Metabolic Syndrome and Its Cardiovascular Complications
Current Hypertension Reviews Editorial [Hot Topic: Gout (Guest Editor: Tony R. Merriman)]
Current Rheumatology Reviews Editorial [ Nuclear Receptors as Drug Discovery Targets Executive Editor: Sunil Nagpal ]
Mini-Reviews in Medicinal Chemistry Epidemiology and Risk Factors of Cerebral Ischemia and Ischemic Heart Diseases: Similarities and Differences
Current Cardiology Reviews Linagliptin: A Novel Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor for Treatment of Type II Diabetes Mellitus
Current Diabetes Reviews Creatine and the Liver: Metabolism and Possible Interactions
Mini-Reviews in Medicinal Chemistry Peri-Procedural Care of Renal Nerve Ablation Candidates
Current Clinical Pharmacology Safety of Vascular Endothelial and Hepatocyte Growth Factor Gene Therapy in Patients with Critical Limb Ischemia
Current Neurovascular Research The Heme Oxygenase System Selectively Modulates Proteins Implicated in Metabolism, Oxidative Stress and Inflammation in Spontaneously Hypertensive Rats
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Neuropharmacology